• +1-646-491-9876
    • +91-20-67278686

    Search

    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015

    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015

    • Report Code ID: RW0001172195
    • Category Pharmaceuticals
    • No. of Pages 39
    • Publication Month Jan-15
    • Publisher Name Global Markets Direct
    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline Review, H1 2015

    Summary

    Publisher's, 'Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline Review, H1 2015', provides an overview of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)'s therapeutic pipeline.

    This report provides comprehensive information on the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

    The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

    Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

    Scope

    - The report provides a snapshot of the global therapeutic landscape of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)
    - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in the therapeutics development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects
    - The report summarizes all the dormant and discontinued pipeline projects
    - A review of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - A detailed assessment of monotherapy and combination therapy pipeline projects
    - Coverage of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type
    - Latest news and deals relating related to pipeline products

    Reasons to buy

    - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Identify and understand important and diverse types of therapeutics under development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)
    - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
    - Devise corrective measures for pipeline projects by understanding Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    Table of Contents
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Global Markets Direct Report Coverage 5
    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 6
    Therapeutics Development 7
    Pipeline Products for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Overview 7
    Pipeline Products for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Comparative Analysis 8
    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Therapeutics under Development by Companies 9
    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline Products Glance 10
    Clinical Stage Products 10
    Early Stage Products 11
    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Products under Development by Companies 12
    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Companies Involved in Therapeutics Development 13
    Human Stem Cells Institute 13
    Juventas Therapeutics, Inc. 14
    Lacer, S.A. 15
    Nuo Therapeutics, Inc. 16
    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Therapeutics Assessment 17
    Assessment by Monotherapy Products 17
    Assessment by Target 18
    Assessment by Mechanism of Action 20
    Assessment by Route of Administration 22
    Assessment by Molecule Type 24
    Drug Profiles 26
    ALD-201-Drug Profile 26
    Product Description 26
    Mechanism of Action 26
    R&D Progress 26
    Biglycan Therapy for Cardiovascular Diseases-Drug Profile 27
    Product Description 27
    Mechanism of Action 27
    R&D Progress 27
    Cryocell-Drug Profile 28
    Product Description 28
    Mechanism of Action 28
    R&D Progress 28
    Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Diseases-Drug Profile 29
    Product Description 29
    Mechanism of Action 29
    R&D Progress 29
    JVS-100-Drug Profile 30
    Product Description 30
    Mechanism of Action 30
    R&D Progress 30
    LA-419-Drug Profile 32
    Product Description 32
    Mechanism of Action 32
    R&D Progress 32
    Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy-Drug Profile 33
    Product Description 33
    Mechanism of Action 33
    R&D Progress 33
    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Recent Pipeline Updates 34
    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Dormant Projects 37
    Appendix 38
    Methodology 38
    Coverage 38
    Secondary Research 38
    Primary Research 38
    Expert Panel Validation 38
    Contact Us 38
    Disclaimer 39

    List of Tables
    Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2015 7
    Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Comparative Analysis, H1 2015 8
    Number of Products under Development by Companies, H1 2015 9
    Comparative Analysis by Clinical Stage Development, H1 2015 10
    Comparative Analysis by Early Stage Development, H1 2015 11
    Products under Development by Companies, H1 2015 12
    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Human Stem Cells Institute, H1 2015 13
    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Juventas Therapeutics, Inc., H1 2015 14
    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Lacer, S.A., H1 2015 15
    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Nuo Therapeutics, Inc., H1 2015 16
    Assessment by Monotherapy Products, H1 2015 17
    Number of Products by Stage and Target, H1 2015 19
    Number of Products by Stage and Mechanism of Action, H1 2015 21
    Number of Products by Stage and Route of Administration, H1 2015 23
    Number of Products by Stage and Molecule Type, H1 2015 25
    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics-Recent Pipeline Updates, H1 2015 34
    Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Dormant Projects, H1 2015 37

    List of Figures
    Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2015 7
    Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Comparative Analysis, H1 2015 8
    Number of Products under Development by Companies, H1 2015 9
    Comparative Analysis by Clinical Stage Development, H1 2015 10
    Assessment by Monotherapy Products, H1 2015 17
    Number of Products by Top 10 Targets, H1 2015 18
    Number of Products by Stage and Top 10 Targets, H1 2015 19
    Number of Products by Top 10 Mechanism of Actions, H1 2015 20
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 21
    Number of Products by Top 10 Routes of Administration, H1 2015 22
    Number of Products by Stage and Top 10 Routes of Administration, H1 2015 23
    Number of Products by Top 10 Molecule Types, H1 2015 24
    Number of Products by Stage and Top 10 Molecule Types, H1 2015 25
    Human Stem Cells Institute
    Juventas Therapeutics, Inc.
    Lacer, S.A.
    Nuo Therapeutics, Inc.

    Request for Sample

    Report Url http://www.reportsweb.com//chronic-coronary-artery-disease-cad-ischemic-heart-disease-pipeline-review-h1-2015&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//chronic-coronary-artery-disease-cad-ischemic-heart-disease-pipeline-review-h1-2015&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//chronic-coronary-artery-disease-cad-ischemic-heart-disease-pipeline-review-h1-2015&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments